Skip to content
Screener

Pre-Tax Income at other companies

Gilead Sciences logo
Gilead SciencesGILD
-$10.25B-522%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$55.09M-11.5%
LQD
Liquidia CorporationLQDA
$56.78M+248%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%
Arrowhead Research logo
Arrowhead ResearchARWR
-$137.57M-137%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$12.79M-83.4%

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest income3,8513,0337,2526,056
Interest expense(2,618)(3,589)(6,234)(7,185)
Other (expense) income, net(24,234)86(24,234)2,194
Net loss before provision for income taxes(65,538)(5,459)(855,218)(19,107)
Provision for income taxes1,6894022,1641,431
Net loss$(67,227)$(5,861)$(857,382)$(20,538)
Net loss per share, basic and diluted$(1.06)$(0.12)$(14.03)$(0.42)
Weighted-average shares of common stock used to compute net loss per share, basic and diluted63,374,18349,726,82361,125,09749,310,255

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s pre-tax income?
Mirum Pharmaceuticals, Inc. (MIRM) reported pre-tax income of -$65.54M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
Mirum Pharmaceuticals, Inc.'s pre-tax income decreased by 1100.5% year-over-year, from -$5.46M to -$65.54M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s pre-tax income?
Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s pre-tax income has grown at a -46.8% compound annual growth rate (CAGR), from -$142.07M to -$21.43M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Mirum Pharmaceuticals, Inc.'s pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude